Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells

被引:0
|
作者
Ferreira, Maria-Jose U.
Duarte, Noelia
Gyemant, Nora
Radics, Rita
Cherepnev, Georgy
Varga, Andras
Molnar, Joseph
机构
[1] Univ Lisbon, CECF, Fac Pharm, P-1699 Lisbon, Portugal
[2] Univ Szeged, Dept Med Microbiol, Szeged, Hungary
[3] Humboldt Univ, Dept Med Immunol Charite, Berlin, Germany
[4] Humboldt Univ, Dept Mol Parasitol, Berlin, Germany
关键词
stilbenes; Euphorbia lagascae; multidrug resistance; apoptosis; CHANNEL BLOCKERS; PICEATANNOL; RESVERATROL; AGENTS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The hydroxystilbene trans-3,5,3,4-tetrahydroxystilbene (piceatannol) (1), isolated from the methanol extract of Euphorbia lagascae defatted seeds, was methylated to yield the derivatives trans-3,5,3,4'-tetramethoxystilbene (2), (trans-3,5-dihydroxy-3', 4'-dimethoxystilbene) (3) and trans-3,5,3'-trihydroxy4'-methoxystilbene (4). The structures of the compounds were assigned by spectroscopic methods (IR, H-1-NMR, C-13-NMR and MS). The ability of piceatannol (1) and the three methylated derivatives to modulate the transport activity of P-glycoprotein (P-gp) and apoptosis induction on the L5178 mouse lymphoma cell line containing the human MDR1 gene was studied by flow cytometry. The reversal of multidrug-resistance (MDR) was investigated by measuring the accumulation of rhodamine-123, a fluorescent substrate analog of doxorubicin, in cancer cells. Verapamil was applied as a positive control. For the evaluation of the compounds as apoptosis inducers, tumor cells were stained with FITC-labelled annexin-V and propidium iodide. The tetramethylated derivative (2) was found to be a powerful inhibitor of P-gp activity. Compounds I and 2 showed an increased apoptotic effect in the MDR subline, the most active being piceatannol (1). Furthermore, in the combination chemotherapy model, the interaction between doxorubicin and the resistance modifier 2 was studied in vitro. The results of checkerboard experiments indicated that the type of interaction was additive between doxorubicin and compound 2 on the human MDR1 gene-transfected mouse lymphoma cells. However, in the MCF7/dox human breast cancer cells, the interaction was non-additive. The degree of additive and non-additive interactions were close to the borderline of the FIX values corresponding to the two types of interactions.
引用
收藏
页码:3541 / 3546
页数:6
相关论文
共 50 条
  • [21] Enhanced doxorubicin transport to multidrug resistant breast cancer cells via TiO2 nanocarriers
    Ren, Wenzhi
    Zeng, Leyong
    Shen, Zheyu
    Xiang, Lingchao
    Gong, An
    Zhang, Jichao
    Mao, Chengwen
    Li, Aiguo
    Paunesku, Tatjana
    Woloschak, Gayle E.
    Hosmane, Narayan S.
    Wu, Aiguo
    RSC ADVANCES, 2013, 3 (43): : 20855 - 20861
  • [22] Poly(L-γ-glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells
    Peng, Ting
    Liu, Kai
    Gao, Liefang
    Gao, Lipeng
    Chen, Jing
    Wang, Jing
    Liu, Yu
    Wang, Yiting
    Yan, Zhiqiang
    Yu, Lei
    MOLECULES, 2016, 21 (06)
  • [23] Optimizing doxorubicin derivatives delivery using temperature sensitive biopolymers in multidrug resistant breast cancer cells
    Dragojevic, Sonja
    Ryu, Jung Su
    Kratz, Felix
    Raucher, Drazen
    CANCER RESEARCH, 2016, 76
  • [24] pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells
    Xia, Yuqiong
    Fang, Mei
    Dong, Jingyu
    Xu, Chunzhong
    Liao, Zhen
    Ning, Pengbo
    Zeng, Qi
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2018, 170 : 514 - 520
  • [25] Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound
    Deng, Zhiting
    Yan, Fei
    Jin, Qiaofeng
    Li, Fei
    Wu, Junru
    Liu, Xin
    Zheng, Hairong
    JOURNAL OF CONTROLLED RELEASE, 2014, 174 : 109 - 116
  • [26] Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin
    Kim, Kwang-Youn
    Kim, Sang-Hun
    Yu, Sun-Nyoung
    Park, Suel-Ki
    Choi, Hyeun-Deok
    Yu, Hak-Sun
    Ji, Jae-Hoon
    Seo, Young-Kyo
    Ahn, Soon-Cheol
    MOLECULAR MEDICINE REPORTS, 2015, 12 (02) : 1898 - 1904
  • [27] Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole
    Desai, PB
    Duan, J
    Sridhar, R
    Damle, BD
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1997, 19 (04): : 231 - 239
  • [28] A New Polymer–Lipid Hybrid Nanoparticle System Increases Cytotoxicity of Doxorubicin Against Multidrug-Resistant Human Breast Cancer Cells
    Ho Lun Wong
    Andrew M. Rauth
    Reina Bendayan
    Janet L. Manias
    Manisha Ramaswamy
    Zengshe Liu
    Sevim Z. Erhan
    Xiao Yu Wu
    Pharmaceutical Research, 2006, 23 : 1574 - 1585
  • [29] TOREMIFENE AND ITS METABOLITES ENHANCE DOXORUBICIN ACCUMULATION IN ESTROGEN-RECEPTOR NEGATIVE MULTIDRUG RESISTANT HUMAN BREAST-CANCER CELLS
    WIEBE, V
    KOESTER, S
    LINDBERG, M
    EMSHOFF, V
    BAKER, J
    WURZ, G
    DEGREGORIO, M
    INVESTIGATIONAL NEW DRUGS, 1992, 10 (02) : 63 - 71
  • [30] Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells
    Shen, Fei
    Chu, Shaoyou
    Bence, Aimee K.
    Bailey, Barbara
    Xue, Xinjian
    Erickson, Priscilla A.
    Montrose, Marshall H.
    Beck, William T.
    Erickson, Leonard C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (01): : 95 - 102